Cerenome

Cerenome is an integrated central nervous system (CNS) oncology company that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with brain and spinal cord cancers. Formerly known as Plus Therapeutics, the company's lead assets include CNSide, a commercially available cerebrospinal fluid-based diagnostic platform, and Reyobiq (rhenium Re186 obisbemeda), a clinical-stage targeted radiotherapeutic. Cerenome focuses on high-unmet-need indications such as leptomeningeal metastases, recurrent glioblastoma, and pediatric brain tumors. By integrating diagnostic insights with therapeutic delivery and AI-driven data analytics, the company aims to provide a comprehensive systems-based approach to managing complex CNS malignancies.